Madison Square Garden Entertainment (NYSE: MSGE) has recently received a number of price target changes and ratings updates:
- 5/9/2026 – Madison Square Garden Entertainment was downgraded by Wall Street Zen from “buy” to “hold”.
- 5/8/2026 – Madison Square Garden Entertainment had its price target raised by JPMorgan Chase & Co. from $63.00 to $67.00. They now have a “neutral” rating on the stock.
- 5/7/2026 – Madison Square Garden Entertainment had its price target raised by BTIG Research from $70.00 to $86.00. They now have a “buy” rating on the stock.
- 5/4/2026 – Madison Square Garden Entertainment was downgraded by Weiss Ratings from “hold (c+)” to “hold (c)”.
- 4/16/2026 – Madison Square Garden Entertainment had its price target raised by Guggenheim from $74.00 to $76.00. They now have a “buy” rating on the stock.
- 4/7/2026 – Madison Square Garden Entertainment is now covered by BTIG Research. They set a “buy” rating and a $70.00 price target on the stock.
- 3/27/2026 – Madison Square Garden Entertainment had its “hold (c)” rating reaffirmed by Weiss Ratings.
Insider Transactions at Madison Square Garden Entertainment
In other news, Director Charles P. Dolan sold 19,311 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $63.76, for a total value of $1,231,269.36. Following the completion of the sale, the director directly owned 660 shares of the company’s stock, valued at approximately $42,081.60. This represents a 96.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 16.41% of the stock is owned by insiders.
The company’s core business activities center on venue management, event promotion and production services.
Featured Stories
- Five stocks we like better than Madison Square Garden Entertainment
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
- The Great AI Rotation: Cashing In on Data
- Mirum Pharma: A Rare Disease Growth Story to Watch
Receive News & Ratings for Madison Square Garden Entertainment Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madison Square Garden Entertainment Corp and related companies with MarketBeat.com's FREE daily email newsletter.
